Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method

Kohei Hara, Atsushi Saito, Keizo Yamaguchi, Yoji Suzuyama, Yoshiteru Shigeno, Shigeru Kohno, Koichi Watanabe, Kin Ichi Izumikawa, Tsunetoshi Koteda, Kazuhiro Okuno, Takashige Miyazaki, Tsuneo Tsutsumi, Masumi Tomizawa, Ichiro Nakayama, Yohmei Hiraga, Kohki Kikuchi, Asako Yamamoto, Kazuo Takebe, Yoshihiro Kumasaka, Kazumi AoyagiToyokazu Tamura, Keiichi Sekino, Tatsuro Irie, Morio Sagara, Katsuhiro Okamoto, Masao Tamura, Kazuki Konishi, Ataru Daibo, Hiroshi Kuramitsu, Kazutoshi Gomi, Kotaro Itakura, Nobuhisa Sato, Kazuo Tanifuji, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Kosaku Nagai, Izumi Hayashi, Masataka Katsu, Shinji Okui, Toshio Fukui, Minoru Sato, Takasht Yokosr, Takeo Toyota, Mieko Kawai, Hajime Yamagata, Teruo Aoyagi, Shigeo Yoshizawa, Tetsuji Katayama, Fuyuhiko Higashi, Gohta Masuda, Masayoshi Negishi, Chenden Young, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Fusanosuke Yamasaki, Yasutoshi Suzuki, Hiroyuki Kobayashi, Kenji Takamura, Hiroaki Takeda, Kota Kono, Masakazu Katoh, Yoshiji Yamane, Keimei Mashimo, Junzaburo Kabe, Hiroyoshi Ishibashi, Yasuyuki Sano, Koichiro Kudo, Yuko Uno, Hideo Ikemoto, Kazuyoshi Watanabe, Hiroichi Tanimoto, Koichiro Nakata, Yoshitaka Nakamori, Naohiko Chonabayashi, Ryuo Nakatani, Kunihiko Yoshimura, Tadashi Miyahara, Masaru Koyama, Kentaro Watanabe, Fukuo Iijima, Yoshio Kobayashi, Ippei Fujimori, Takehiko Tominaga, Takao Okubo, Akira Ito, Makio Kurihara, Kaitaro Yamabe, Kazufuto Fukaya, Fumio Matsumoto, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Koou Murohashi, Hisako Suzuki, Yasuhiro Yoshiike, Mitsuyo Kiuchi, Tsutomu Fukuda, Kaoru Oyama, Toshihiko Takeuchi, Masahito Kato, Hidekazu Hanaki, Toshiyuki Yamamoto, Hideki Nishiyama, Takekuni Iwata, Kazukiyo Oida, Yoshiro Mochizuki, Mitsuo Hase, Yujiro Suzuki, Nobuaki Ikeda, Shozo Fujino, Tetsuya Matsumoto, Hiroyuki Tsujino, Kenji Bando, Naoaki Kuroda, Fumiyuki Kuze, Yuruko Okamoto, Seibun Yonezu, Yube Iida, Yoshihiko Sakakibara, KōZiro Yasunaga, Yoshihiro Ueda, Hiroshi Okubo, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shin Ichi Tanizawa, Kazuo Sakamoto, Hirozumi Sakai, Rinzo Soejima, Hiroshi Kawane, Yoshihito Niki, Yoshihisa Nakagawa, Osamu Moriya, Eiro Tsubura, Masakazu Tamura, Toshihiro Gotoh, Masaru Nakagawa, Koichi Fukuyama, Tadaaki Morimoto, I. Teiho, Masami Ito, Naoyoshi Kojiro, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Tadao Morimoto, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Hitoshi Nagano, Torao Inoue, Chiharu Kubo, Keizo Matsumoto, Harumi Shishido, Tomoyuki Harada, Masaru Nasu, Jun Goto, Yoichiro Goto, Takayoshi Tashiro, Takashi Itoga, Moritaka Suga, Masayuki Ando, Shukuro Araki, Kazumine Kobari, Masao Nakatomi, Yutoku Kinjo, Tatsuo Ohgimi, Katsuyoshi Shimoji, Yuei Irabu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The clinical effectiveness and safety of BAY o 9867 (Ciprofloxacin, CPFX) in the treatment of the patients with bacterial pneumonia were compared with those of bacampicillin (BAPC) by a double-dummy fashion. Patients over 18 years old with apparent clinical signs and symptoms of pneumonia were administered with CPFX at a daily dose of 600 mg or BAPC at a daily dose of 1 g orally for 14 days in principle. The following results were obtained. 1) On the basis of committee judgement, the clinical efficacy rate in the total cases including non-bacterial pneumonia was 85.3% (58/68) in CPFX group and 90.5% (57/63) in BAPC group, respectively. In bacterial pneumonia, the rate was 83.3% (45/54) in CPFX group and 88. 9% (40/45) in BAPC group, respectively. The differences between the two groups in both analyses were statistically not significant. 2) The clinical efficacy rate by doctors in charge in the total cases was 87.7% (57/65) in CPFX group and 86.9% (53/61) in BAPC group, respectively. In bacterial pneumonia, the rate was 86.8% (46/53) for CPFX group and 87.2% (41/47) for BAPC group, respectively. In both analyses, the differences between the two groups were statistically not significant. 3) As for the bacteriological response, the eradication rate in the total cases was 85.7% (18/21) in CPFX group and 65. 0% (13/20) in BAPC group, respectively. In bacterial pneumonia, the eradication rate was 83.3% (15/18) in CPFX group and 56.3% (9/16) in BAPC group, respectively. In both analyses, the rates of CPFX were higher than those of BAPC, but statistically, the differences between the two groups were not significant. 4) Side effects were noted in 7 of 83 cases (8. 4%) treated with CPFX and 8 of 84 cases (9. 5%) with BAPC, and abnormal changes in laboratory findings were noted in 12 of 80 cases (15.0%) with CPFX and 18 of 77 cases (23.4%) with BAPC. The differences between the two groups were not significant statistically. Neither serious side effect nor remarkable abnormal change in laboratory findings was noted. 5) The utility rates judged by the committee members and by doctors in charge were not significantly different between the two groups. From these results, it is considered that the clinical efficacy and safety of CPFX at a daily dose of 600 mg are equal to those of BAPC at a daily dose of 1g in the treatment of the patients with bacterial pneumonia.

Original languageEnglish
Pages (from-to)629-653
Number of pages25
JournalChemotherapy
Volume34
Issue number7
DOIs
Publication statusPublished - Jan 1 1986

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Hara, K., Saito, A., Yamaguchi, K., Suzuyama, Y., Shigeno, Y., Kohno, S., ... Irabu, Y. (1986). Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method. Chemotherapy, 34(7), 629-653. https://doi.org/10.11250/chemotherapy1953.34.629